Products
Plonmarlimab Biosimilar Monoclonal Antibody (GM-CSF) for Research
Pre-Made Plonmarlimab biosimilar, Whole mAb, Anti-CSF2 Antibody: Anti-CSF/GMCSF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Plonmarlimab [previously TJM 2 (TJ 003234)] is a first-in-class, humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting neutralise.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-453-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Plonmarlimab biosimilar, Whole mAb, Anti-CSF2 Antibody: Anti-CSF/GMCSF therapeutic antibody |
| INN Name | Plonmarlimab |
| Target | CSF2 |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II/III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | na |
| Companies | I-Mab Biopharma |
| Conditions Approved | na |
| Conditions Active | Rheumatoid arthritis;COVID-19;Osteoarthritis |
| Conditions Discontinued | na |
| Development Tech | na |
About target - CSF2
1. Protein Granulocyte-macrophage colony-stimulating factor
2. Gene CSF2
3. Organism Homo sapiens (Human)
Function
Cytokine that stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes.
